scholarly journals Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis?

2010 ◽  
Vol 19 (6) ◽  
pp. 799-806 ◽  
Author(s):  
Sonja Lüer ◽  
Rolf Troller ◽  
Marion Jetter ◽  
Violeta Spaniol ◽  
Christoph Aebi
Keyword(s):  
Cancer Therapy ◽  
Respiratory Tract ◽  
Potential Role ◽  
Upper Respiratory Tract ◽  
Patients With Cancer ◽  
Upper Respiratory

scholarly journals Kinetics of BoHV-1 Dissemination in an in Vitro Culture of Bovine Upper Respiratory Tract Mucosa Explants

ILAR Journal ◽  
2012 ◽  
Vol 53 (1) ◽  
pp. E43-E54 ◽  
Author(s):  
L. Steukers ◽  
A. P. Vandekerckhove ◽  
W. Van den Broeck ◽  
S. Glorieux ◽  
H. J. Nauwynck
Keyword(s):  
Respiratory Tract ◽  
In Vitro Culture ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Kinetics Of

scholarly journals Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses

2021 ◽  
Vol 8 ◽  
Author(s):  
Bianca Schulte ◽  
Benjamin Marx ◽  
Marek Korencak ◽  
Dorian Emmert ◽  
Souhaib Aldabbagh ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Tract ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Upper Respiratory Tract ◽  
Protective Measures ◽  
Specific Antibodies ◽  
Household Members ◽  
Upper Respiratory

We present a case of SARS-CoV-2 B.1. 525 infection in a healthcare worker despite the presence of highly neutralizing, multivariant-specific antibodies 7 weeks after full vaccination with the mRNA vaccine BNT162b2. We show that the virus replicated to high levels in the upper respiratory tract over the course of several days in the presence of strong antibody responses. The virus was readily propagatable in vitro, demonstrating the potential to transmit to others, bolstered by the fact that several household members were equally infected. This highlights the importance of protective measures even in vaccinated individuals.

Antiviral Properties of Food Plants Could Help to Reduce Contagion and Severity in SARS-CoV-2 Infections

2021 ◽  
Vol 07 ◽  
Author(s):  
Betina Cardoso
Keyword(s):  
Respiratory Tract ◽  
Literature Search ◽  
Food Plants ◽  
Upper Respiratory Tract ◽  
Site Specific ◽  
In Vivo Experiments ◽  
Upper Respiratory ◽  
Novel Coronavirus

Introduction: The importance of an immediate tool to help patients and prevent viral diffusion of new pneumonia caused by 2019 novel coronavirus (2019-nCoV or SARS-CoV-2) that causes the disease COVID-19 becomes evident. Recent articles have reported on body site-specific SARS-CoV-2 infection, showing very active replication in the throat and upper respiratory tract when symptoms were still mild, and thus being efficient in viral transmission in sputum. Material and Methods: An alternative that may be feasible is to resort to scientific studies that demonstrate the antiviral potential of medicinal plants species through in-vitro and in-vivo experiments to alleviate symptoms and prevent the spread of contagion. A literature search in Scopus and PubMed on herbs and foods with antiviral properties was performed. Results: Herbs and foods with demonstrated antiviral potential have been identified, which could limit SARS-CoV-2 spreading by interfering on ACE2 protein on infection sites. The analysis of transdisciplinary knowledge allows us to connect previous research on the action of common plants and foods on viruses to limit the replication of SARS-CoV-2 in the throat and upper respiratory tract. Conclusions: Herbs and foods with demonstrated antiviral potential have been identified, which could limit SARS-CoV-2 spreading by interfering on ACE2 protein on infection sites. The analysis of transdisciplinary knowledge allows us to connect previous research on the action of common plants and foods on viruses to limit the replication of SARS-CoV-2 in the throat and upper respiratory tract.

Antibiotic Resistance: Relationship to Persistence of Group A Streptococci in the Upper Respiratory Tract

PEDIATRICS ◽  
1996 ◽  
Vol 97 (6) ◽  
pp. 971-975
Author(s):  
Michael A. Gerber
Keyword(s):  
Respiratory Tract ◽  
Upper Respiratory Tract ◽  
Beta Lactam ◽  
Erythromycin Resistance ◽  
In Vitro Susceptibility ◽  
Beta Lactam Antibiotics ◽  
Group A ◽  
Resistant Strains ◽  
Upper Respiratory

Despite the use of penicillin for more than 40 years in treating GABHS infections, there has been no significant change in the in vitro susceptibility of GABHS to penicillin. Reported failures to eradicate GABHS from the upper respiratory tracts of patients with pharyngitis and the apparent resurgence of serious Group A streptococcal infections and their sequelae probably are not related to the emergence of penicillin resistance. Although erythromycin resistance in GABHS had been a major problem in Japan and continues to be a major problem in Finland, it has not been a problem in this country. The susceptibility of GABHS to the newer macrolide antibiotics appears to be similar to that of erythromycin. Comprehensive, community-wide programs to continuously monitor for erythromycin resistance in GABHS would be difficult to justify. However, because little is known about how erythromycin resistance in GABHS is acquired or spread, it would be reasonable to periodically monitor isolates of GABHS for erythromycin resistance. A substantial proportion of GABHS are currently resistant to tetracyclines and these agents are inappropriate for treating GABHS infections. Although little recent information is available about the susceptibility of GABHS to sulfonamides, these agents have been shown to be ineffective in eradicating GABHS from the upper respiratory tract regardless of the in vitro sensitivities. GABHS have not been shown to be resistant to any of the commonly used oral cephalosporins; however, there is a great deal of variability among these agents in their activity against GABHS. Clindamycin resistance in GABHS has remained unusual. This agent is an alternative for treating GABHS infections due to macrolide-resistant strains in patients who cannot be treated with beta-lactam antibiotics. There is no reason, based on the in vitro susceptibilities of GABHS, to change the current recommendations for treating GABHS infections with penicillin and for using erythromycin for patients who are allergic to penicillin.

A rat nasal epithelial model for predicting upper respiratory tract toxicity: in vivo–in vitro correlations

Toxicology ◽  
2000 ◽  
Vol 145 (1) ◽  
pp. 39-49 ◽  
Author(s):  
J.D Kilgour ◽  
S.A Simpson ◽  
D.J Alexander ◽  
C.J Reed
Keyword(s):  
Respiratory Tract ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

Fungal colonization in patients with cancer of the upper respiratory tract

1986 ◽  
Vol 96 (2) ◽  
pp. 97-101 ◽  
Author(s):  
V. Vidotto ◽  
M. Clerico ◽  
L. Franzin ◽  
L. Lucchini ◽  
A. Sinicco
Keyword(s):  
Respiratory Tract ◽  
Fungal Colonization ◽  
Upper Respiratory Tract ◽  
Patients With Cancer ◽  
Upper Respiratory

scholarly journals Demonstration of N , N -Dimethyldithiocarbamate as a Copper-Dependent Antibiotic against Multiple Upper Respiratory Tract Pathogens

2021 ◽  
Author(s):  
Sanjay V. Menghani ◽  
Angela Rivera ◽  
Miranda Neubert ◽  
James R. Hagerty ◽  
Lourdes Lewis ◽  
...  
Keyword(s):  
Antibiotic Resistance ◽  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Dependent Manner ◽  
Upper Respiratory Tract ◽  
Coccidioides Posadasii ◽  
Content Type ◽  
Upper Respiratory

With the rise of antibiotic resistance, approaches that add new antimicrobials to the current repertoire are vital. Here, we investigate putative and known copper ionophores in an attempt to intoxicate bacteria and use ionophore/copper synergy, and we ultimately find success with N , N -dimethyldithiocarbamate (DMDC). We show that DMDC has in vitro efficacy in a copper-dependent manner and kills pathogens across three different kingdoms, Streptococcus pneumoniae ( Sr. pneumoniae ), Coccidioides posadasii , and Schistosoma mansoni , and in vivo efficacy against Sr . pneumoniae .

ERYTHROMYCIN IN THE TREATMENT OF DIPHTHERIA AND DIPHTHERIA CARRIER STATE

PEDIATRICS ◽  
1955 ◽  
Vol 16 (3) ◽  
pp. 335-344
Author(s):  
M. W. Beach ◽  
W. B. Gamble ◽  
C. H. Zemp ◽  
Margaret Q. Jenkins
Keyword(s):  
Clinical Trial ◽  
Respiratory Tract ◽  
Carrier State ◽  
Considerable Importance ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Nose And Throat ◽  
Active Disease ◽  
Primary Form

The treatment of acute diphtheria has not been drastically changed by the use of antibiotics. Antitoxin remains the primary form of therapy. However, the eradication of virulent diphtheria bacilli from the upper respiratory tract of patients with the active disease and of carriers is of considerable importance in the control of the disease. Streptomycin is effective in vitro and in infections produced experimentally but it has not been clinically evaluated in acute diphtheria or in the carrier state. Chlortetracycline, chloramphenicol, and oxytetracyline, although active against the causative organisms, have not had sufficient clinical trial to permit evaluation in the control of diphtheria and the carrier state. Penicillin eradicates C. diphtheriae from the nasopharynx in 75 per cent of patients within a period of 3 to 4 days. In this study erythromycin eradicated the C. diptheriae from the nose and throat in all of the cases in an average of 2 days in the active cases and in an average of 3 days in the carrier state. In the treatment of diphtheria erythromycin appears on the basis of the present and of previous studies to be the most promising antibiotic developed to date. Erythromycin is advocated as an adjunct to and not as a substitute for antitoxin in the treatment of acute diphtheria.

Sign in / Sign up

Export Citation Format

Share Document